In biotech, capital is a lifeline. Scientific progress alone doesn’t bring therapies to patients; sustained funding helps. With long development timelines and high burn rates, biotech companies must ...
The success of the company’s IPO is a sign that investors are putting their money behind sustainability-driven companies. But there may be limits to how far environmental, social, and governance (ESG) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback